Latest News — Page 11

Is Portugal’s cannabis market hitting the brakes? 📉🇵🇹

Recent cuts in licensing have visibly contracted the sector — reducing new entrants, cooling investment, and creating supply and patient-access pressures while forcing companies to reassess growth strategies. The article explains the regulatory shifts, market impacts, and what policymakers and businesses can do next.

Read the full analysis to understand the implications and next steps for stakeholders.

#SyenzaNews #regulatoryaffairs #pharmaceuticals #MarketAccess #governance

Can local vaccine manufacturing finally deliver supply security for Africa? 🌍🏭

This article breaks down the practical opportunities and hurdles — from technology transfer and workforce development to financing, regulatory alignment, and regional partnerships — that will determine whether African countries can reduce import dependence and respond faster to future outbreaks. It highlights actionable strategies and policy priorities to scale sustainable, region-wide production.

Read the full piece to explore country examples, investment pathways, and next steps for policymakers and industry.

#SyenzaNews #pharmaceuticals #globalhealth #innovation #healthcarepolicy

Could NICE’s approval of durvalumab reshape gastric cancer care in the UK?

NICE has recommended durvalumab for gastric cancer after an appraisal that weighed clinical benefit and cost-effectiveness, opening the door to broader NHS access and changes to treatment pathways. The article explains the decision drivers, likely timelines for patient access, and implications for clinicians and industry.

Read the full piece to get the details and what to expect next. 🔍

#SyenzaNews #oncology #regulatoryaffairs #MarketAccess #healthcarepolicy

How do bladder cancer treatments affect patients’ quality of life?

This article unpacks the real-world consequences of choices from bladder‑sparing therapies to radical cystectomy and urinary diversion—covering impacts on urinary function, sexual health, body image and psychosocial wellbeing. It also highlights the value of patient‑reported outcomes, multidisciplinary care, and emerging approaches that aim to preserve function and dignity. 🔍🩺

Read the full piece to weigh trade‑offs and discover patient‑centered strategies that improve everyday life for people with bladder cancer.

#SyenzaNews #oncology #HealthcareInnovation #innovation #healthcarepolicy

Can pharmacy-led vaccination programs scale globally without a major training overhaul? 💉🌍

Standardized competency-based curricula, scalable digital learning, and regulatory alignment are critical to prepare pharmacists for safe, widespread vaccine delivery. Coupled with practical supervision, cold-chain investment, and accreditation, these steps can expand access and strengthen pandemic resilience.

Read the full article for practical strategies and policy recommendations to accelerate pharmacy vaccination training worldwide.

#SyenzaNews #pharmaceuticals #globalhealth #healthcarepolicy #innovation

Are you up to date with NICE NG195 on neonatal infection management? 👶🩺

NICE’s new guidance promotes a risk‑based approach to starting and stopping empirical antibiotics, clarifies diagnostic testing and duration decisions, and strengthens antimicrobial stewardship while centering family involvement.

Explore the full article for practical takeaways and what this means for clinicians and neonatal units.

#SyenzaNews #healthcare #HealthcareInnovation #healthcarepolicy #innovation

🌟 How are Merck’s advancements in oncology reshaping cancer treatment?

With significant new data set to be unveiled at ASCO 2026, Merck is enhancing treatment options for cancers like melanoma and lung cancer, demonstrating long-term survival benefits through innovative therapy combinations.

Dive into the insights from their presentations and discover how these breakthroughs could impact patient care.

#SyenzaNews #oncology #drugdevelopment #HealthcareInnovation

Can the EU’s Critical Medicines Act finally end chronic drug shortages? 💊🔗

The new legislation aims to shore up pharma supply chains by diversifying suppliers, boosting on‑shore production and API capacity, and tightening shortage monitoring and joint procurement — shifting regulatory expectations and commercial incentives across the sector. It’s a pivotal moment for manufacturers, regulators and healthcare providers to reassess supply‑chain resilience and investment priorities.

Read the full article for a practical breakdown of the Act’s measures and what steps organisations should take next.

#SyenzaNews #pharmaceuticals #regulatoryaffairs #healthcarepolicy #strategicplanning

🌟 Are you ready to revolutionize mental health care?

Innovations in neuropsychiatry are paving the way for enhanced treatment options for complex conditions like major depressive disorder and schizophrenia. Recent findings from Johnson & Johnson highlight significant advancements that could improve patient outcomes and reduce long-term costs associated with relapse.

Curious to learn how these breakthroughs are shaping the future of mental health treatment? Dive into the full article for a comprehensive analysis!

#SyenzaNews #HealthcareInnovation #MentalHealth #Innovation

Could marstacimab reshape hemophilia care in Portugal? 📊

A new cost‑effectiveness analysis models marstacimab versus standard prophylaxis and finds it may deliver better bleed prevention and quality‑adjusted life‑years at an acceptable incremental cost, with meaningful implications for budget impact and reimbursement decisions. The results give payers, clinicians, and policymakers clearer evidence to inform market access strategies.

Read the full analysis to review the assumptions, sensitivity checks, and what this could mean for patients and the health system.

#SyenzaNews #HealthEconomics #pharmaceuticals #costeffectiveness #Economicevaluation

Can Managed Entry Agreements unlock sustainable access to ATMPs without breaking healthcare budgets? 🔬

This piece breaks down the key barriers—uncertain long-term outcomes, data gaps, and pricing complexity—and presents practical strategies like real-world evidence frameworks, risk‑sharing models, and adaptive contracts to align payers, manufacturers, and regulators.

Read the full article to explore actionable approaches for designing MEAs that balance innovation, affordability, and patient access. 💡

#SyenzaNews #pharmaceuticals #regulatoryaffairs #MarketAccess #costeffectiveness

Could biocatalysis be the key to the first oral PCSK9 inhibitor? 🔬💊

A recent breakthrough in biocatalytic synthesis is enabling scalable, stereoselective routes to small-molecule PCSK9 inhibitors — potentially turning today’s injectable therapies into convenient, lower-cost oral medicines with better patient adherence. This could reshape cardiovascular drug development, manufacturing economics, and market access.

Read the full article to see the science, commercial implications, and next steps for bringing oral PCSK9s to patients.

#SyenzaNews #biotechnology #drugdevelopment #innovation #MarketAccess

Is your GMP manufacturing program ready for EMA scrutiny around AI? 🤖🏭

The recent EMA workshop lays out practical expectations for using AI/ML in GMP — from validation and data integrity to risk management, human oversight, and continuous monitoring to safeguard product quality.

Read the full article for key takeaways and actionable steps to align your AI initiatives with regulatory expectations.

#SyenzaNews #pharmaceuticals #regulatoryaffairs #ai #innovation

Are developers missing the mark on stakeholder engagement in advanced therapies? 🔬

The article shows how misaligned priorities between developers, clinicians, payers and patients can derail adoption of cell and gene therapies, and offers practical fixes—early payer evidence planning, cross-functional commercialization teams, scalable manufacturing strategies, and patient-centric support—to bridge the gap.

Read the full piece to learn actionable steps for aligning development and engagement to speed access and commercial success. 💡

#SyenzaNews #biotechnology #drugdevelopment #MarketAccess #innovation

Are MEA health systems ready for the cost and complexity of ATMPs? 💡

This article breaks down the key reimbursement barriers—high upfront costs, limited HTA and regulatory capacity, infrastructure and manufacturing gaps—and proposes practical solutions like outcomes-based contracts, real-world evidence generation, and regional capacity building to improve patient access.

Read the full piece for strategic recommendations for payers, manufacturers, and policymakers.

#SyenzaNews #HealthEconomics #regulatoryaffairs #MarketAccess #healthcarepolicy

Is fragmented care leaving the Netherlands’ elderly behind? 🧭

This piece breaks down how a patchwork of providers, funding streams and limited data-sharing creates gaps in continuity, workforce strain and regional inequities. It also outlines practical levers—regional care networks, stronger case management and interoperable systems—to rebuild coordination and equity.

Read the full analysis to see the policy and operational steps needed to make elderly care more integrated and sustainable.

#SyenzaNews #healthcare #HealthEconomics #healthcarepolicy #resourceallocation